

## Users of prescription drugs (NHC) – users per 1000 inhabitants, age standardised

Year				2005	2006	2007	2008	2009	2010	2011	2012	2013	2014		
Geography	Drug group	Age	Gender												
Nordland	Total all drug groups	0-74 yrs	both genders	652	663	661	669	679	669	673	670	662	664		
			men	580	593	592	603	618	604	608	606	594	595		
			women	727	737	735	738	743	738	742	738	735	738		
		0-44 yrs	both genders	572	584	579	587	600	586	591	584	573	577		
			men	490	503	498	510	529	509	513	508	491	494		
			women	657	669	664	670	675	669	673	666	662	666		
		0-17 yrs	both genders	421	433	411	431	451	439	447	434	414	428		
			men	416	424	404	423	451	432	441	429	405	418		
			women	426	443	419	439	453	447	453	438	422	439		
		18-24 yrs	both genders	643	664	674	674	686	670	674	673	672	666		
			men	448	475	486	493	518	491	498	496	482	479		
			women	855	869	877	870	869	868	869	869	882	874		
		25-44 yrs	both genders	670	679	683	686	692	678	680	677	671	668		
			men	565	576	579	586	597	578	578	577	564	561		
			women	780	786	791	790	792	782	786	784	783	780		
		45-74 yrs	both genders	792	803	807	812	817	814	817	821	817	818		
			men	737	752	757	767	775	771	775	778	774	773		
			women	850	857	860	859	861	860	862	865	863	865		
		0-79 yrs	both genders	659	670	669	676	686	677	680	678	670	672		
			men	589	602	601	612	627	613	617	616	603	605		
			women	733	742	741	744	749	744	747	744	741	744		
		18-79 yrs	both genders	732	743	748	752	758	749	752	753	749	747		
			men	642	657	662	670	681	669	672	673	664	662		
			women	827	834	839	837	839	835	838	838	839	837		
			Diabetes drugs (A10)	0-74 yrs	both genders	21	22	24	25	26	27	26	26	27	27



	men	3	3	3	3	3	3	4	3	3	3	
	women	2	2	3	3	3	3	3	3	2	2	
18-24 yrs	both genders	5	5	5	6	6	6	6	6	6	7	
	men	6	6	6	7	7	7	7	7	7	7	
	women	3	4	4	5	5	5	5	5	6	6	
25-44 yrs	both genders	8	8	8	8	8	9	8	8	8	8	
	men	8	9	9	9	9	10	10	9	10	10	
	women	7	7	7	7	7	7	7	7	7	7	
45-74 yrs	both genders	17	17	18	18	18	19	19	19	19	19	
	men	20	20	21	22	22	22	23	22	22	23	
	women	14	14	14	14	15	16	15	15	16	15	
0-79 yrs	both genders	10	10	11	11	11	11	11	11	11	11	
	men	12	12	12	13	13	13	13	13	13	13	
	women	9	9	9	9	9	9	10	9	10	9	
18-79 yrs	both genders	13	13	13	13	14	14	14	14	14	14	
	men	14	15	15	16	16	16	16	16	16	16	
	women	11	11	11	11	11	12	12	12	12	12	
Cardiovascular disease, treatment/prevention (C)	0-74 yrs	both genders	149	153	158	162	165	167	168	168	167	167
		men	148	153	158	162	166	169	172	171	171	171
		women	150	154	159	162	163	164	164	164	163	162
0-44 yrs	both genders	31	32	33	35	35	37	38	39	40	40	
	men	29	30	31	33	33	35	36	37	37	38	
	women	33	34	35	37	38	38	39	41	43	43	
0-17 yrs	both genders	5	5	5	6	7	7	9	9	10	11	
	men	5	6	6	6	7	8	9	10	10	12	
	women	4	4	5	7	6	7	8	9	10	10	
18-24 yrs	both genders	15	14	16	17	19	20	21	22	22	24	
	men	11	10	11	12	14	15	16	16	15	18	
	women	19	18	21	22	23	25	28	28	29	30	
25-44 yrs	both genders	58	60	62	64	64	66	67	69	70	69	

	men	54	56	59	61	60	63	65	66	66	66	
	women	62	63	65	67	68	68	68	71	74	73	
45-74 yrs	both genders	357	366	378	386	392	395	396	394	391	389	
	men	359	368	379	390	399	405	409	406	406	405	
	women	355	364	377	381	384	385	383	380	375	371	
0-79 yrs	both genders	164	168	174	178	180	183	184	184	183	183	
	men	163	167	173	178	182	185	187	187	187	187	
	women	165	169	175	177	179	180	180	180	179	178	
18-79 yrs	both genders	213	218	225	230	234	236	238	237	237	235	
	men	212	217	224	231	235	239	242	241	241	241	
	women	214	219	227	230	232	233	233	233	232	229	
Cardiovascular disease, treatment/prevention, except lipid modifying agents (C except C10)	0-74 yrs	both genders	132	134	137	140	141	142	143	144	144	144
		men	132	134	137	141	143	146	147	147	148	148
		women	132	135	137	139	139	139	139	140	140	140
0-44 yrs	both genders	27	28	29	30	31	32	33	34	36	36	
	men	24	25	26	27	27	29	30	31	32	33	
	women	31	31	32	34	34	35	36	37	40	40	
0-17 yrs	both genders	5	5	5	6	7	7	8	9	10	11	
	men	5	6	6	6	7	8	9	10	10	12	
	women	4	4	5	6	6	7	7	8	9	10	
18-24 yrs	both genders	13	13	15	16	17	19	20	21	21	22	
	men	10	9	10	11	12	13	15	15	15	17	
	women	18	16	20	21	23	24	27	27	28	29	
25-44 yrs	both genders	51	52	53	55	55	56	57	59	62	62	
	men	45	47	47	49	49	51	52	55	56	56	
	women	57	58	59	60	60	61	62	65	68	68	
45-74 yrs	both genders	314	321	327	332	335	337	337	336	335	334	
	men	320	325	332	341	345	351	352	351	351	351	
	women	308	316	321	323	325	322	320	320	317	315	
0-79 yrs	both genders	146	149	152	155	156	158	158	159	159	159	

		men	146	149	152	156	158	161	162	163	163	163	
		women	146	149	152	153	155	154	154	155	155	155	
	18-79 yrs	both genders	189	193	197	200	202	204	204	205	205	204	
		men	189	192	197	202	205	208	209	209	210	210	
		women	189	193	197	198	200	200	200	201	200	199	
Lipid modifying agents (C10)	0-74 yrs	both genders	65	70	76	79	82	83	83	81	79	77	
		men	72	77	82	86	89	92	93	91	89	88	
		women	58	63	69	72	74	75	73	71	68	65	
	0-44 yrs	both genders	6	7	8	8	8	9	8	8	7	7	
		men	8	9	10	11	10	11	11	10	10	9	
		women	5	5	6	6	6	6	5	5	5	4	
	0-17 yrs	both genders	0	0	0	0	0	0	0	0	0	0	
		men	:	:	:	:	:	:	:	:	:	:	
		women	:	:	:	:	:	:	:	:	:	:	
	18-24 yrs	both genders	1	1	1	1	2	1	1	1	1	1	
		men	:	:	:	1	2	2	:	1	1	1	
		women	:	:	:	1	1	1	:	1	1	2	
	25-44 yrs	both genders	13	14	16	17	17	18	17	16	15	14	
		men	17	18	21	22	22	23	23	22	21	20	
		women	9	10	11	12	13	12	11	10	9	8	
	45-74 yrs	both genders	169	180	195	204	210	215	215	211	205	199	
		men	184	196	210	219	227	233	237	233	228	225	
		women	153	164	179	187	192	195	193	187	180	173	
	0-79 yrs	both genders	73	78	84	88	91	93	94	91	89	87	
		men	:	:	:	96	99	102	:	102	99	98	
		women	:	:	:	81	83	85	:	81	78	75	
	18-79 yrs	both genders	95	101	110	115	119	122	122	119	116	113	
		men	104	111	119	125	130	133	135	133	130	128	
		women	85	92	101	105	109	110	109	105	102	98	
	Painkillers (analgetics) (M01A, N02A, N02B)	0-74 yrs	both genders	218	223	228	227	220	223	219	220	220	218

	men	194	198	201	203	198	200	196	196	196	191	
	women	244	250	255	252	244	246	244	246	246	247	
0-44 yrs	both genders	153	156	161	159	154	154	151	151	150	147	
	men	140	141	146	144	139	140	135	134	132	127	
	women	167	172	178	175	169	170	169	169	168	168	
0-17 yrs	both genders	25	26	28	28	27	27	26	28	27	26	
	men	21	20	22	23	22	22	22	23	22	21	
	women	29	33	34	34	33	33	31	32	32	32	
18-24 yrs	both genders	153	160	173	170	159	160	155	157	156	152	
	men	130	132	147	142	135	137	129	130	129	120	
	women	177	191	202	200	185	186	184	188	186	187	
25-44 yrs	both genders	257	261	266	262	256	256	252	249	248	243	
	men	239	243	246	243	237	237	229	225	224	215	
	women	276	280	287	283	275	276	276	274	273	272	
45-74 yrs	both genders	333	341	344	345	336	343	339	343	344	344	
	men	290	297	299	306	300	307	304	304	307	305	
	women	378	387	391	386	374	381	376	382	382	385	
0-79 yrs	both genders	223	227	232	231	225	227	224	225	225	223	
	men	198	201	205	206	201	204	200	199	199	195	
	women	248	255	260	257	249	251	249	252	251	252	
18-79 yrs	both genders	283	289	294	293	286	289	285	286	286	283	
	men	252	256	261	262	257	260	255	253	254	249	
	women	316	323	329	325	315	318	316	319	318	320	
Antiinflammatory and antirheumatic products, non-steroids (M01A)	0-74 yrs	both genders	174	179	182	179	172	174	169	167	166	161
		men	153	156	160	159	154	157	151	148	148	142
		women	196	203	206	200	191	192	189	187	184	181
	0-44 yrs	both genders	125	128	133	130	124	124	120	117	117	113
		men	114	115	119	118	113	113	107	104	104	98
		women	137	143	147	143	136	136	134	131	131	128
	0-17 yrs	both genders	21	22	23	23	22	22	21	22	21	21

	men	16	15	18	18	17	17	16	17	16	16	
	women	25	29	28	29	28	27	26	27	26	26	
18-24 yrs	both genders	126	134	144	140	128	128	124	121	123	116	
	men	108	109	122	120	110	110	101	98	103	93	
	women	145	162	169	162	149	148	149	147	146	141	
25-44 yrs	both genders	211	213	219	214	206	206	200	194	193	186	
	men	196	197	201	198	192	193	183	177	176	166	
	women	226	230	237	230	220	220	217	211	211	206	
45-74 yrs	both genders	260	268	269	265	257	262	255	254	252	246	
	men	222	229	231	232	228	234	227	225	226	220	
	women	300	308	308	300	288	291	284	283	278	274	
0-79 yrs	both genders	176	181	184	180	174	176	171	168	167	162	
	men	155	157	161	160	156	158	152	149	149	143	
	women	198	205	208	202	193	194	190	188	186	183	
18-79 yrs	both genders	224	229	233	229	221	223	217	213	212	206	
	men	197	201	205	203	198	201	193	190	190	182	
	women	251	259	262	255	244	245	241	238	235	230	
Painkillers, Opioids (N02A)	0-74 yrs	both genders	85	86	88	90	88	88	86	90	90	91
		men	78	79	79	82	80	80	78	82	82	82
		women	94	94	98	99	95	97	95	97	98	100
	0-44 yrs	both genders	56	57	59	60	59	59	58	60	60	59
		men	53	53	54	54	54	53	52	55	54	53
		women	60	61	65	66	64	65	64	65	66	66
	0-17 yrs	both genders	5	5	6	6	5	5	5	6	6	5
		men	4	5	5	5	5	5	5	5	5	4
		women	5	5	7	7	6	6	5	6	7	6
18-24 yrs	both genders	51	51	59	57	56	56	58	60	61	58	
	men	42	42	48	44	46	48	47	53	50	46	
	women	61	60	72	71	66	65	69	69	73	72	
25-44 yrs	both genders	100	101	103	104	104	104	101	103	104	104	

	men	95	97	96	97	97	94	92	96	96	94	
	women	106	107	110	112	111	114	110	112	112	114	
45-74 yrs	both genders	136	137	139	144	138	139	136	142	142	146	
	men	122	124	122	130	126	126	124	130	131	134	
	women	152	151	156	159	150	152	149	154	155	159	
0-79 yrs	both genders	88	89	91	93	90	91	89	92	93	93	
	men	80	81	81	84	82	82	81	84	84	84	
	women	97	97	101	103	98	100	98	100	101	103	
18-79 yrs	both genders	114	115	117	120	116	117	115	119	119	121	
	men	103	105	104	108	106	106	104	108	108	109	
	women	125	125	131	132	127	129	126	129	130	133	
Painkillers, other (N02B)	0-74 yrs	both genders	29	32	40	46	49	53	59	63	65	69
		men	23	25	32	37	39	42	46	49	50	52
		women	35	39	49	56	59	64	72	77	80	87
0-44 yrs	both genders	16	18	25	28	29	31	35	36	37	38	
	men	13	15	21	23	25	25	27	29	28	28	
	women	19	21	28	33	34	37	42	44	45	49	
0-17 yrs	both genders	3	3	5	5	5	5	6	6	6	6	
	men	3	3	4	4	4	4	5	6	5	5	
	women	3	4	6	6	6	7	7	6	6	7	
18-24 yrs	both genders	12	15	24	27	26	28	30	31	31	32	
	men	11	13	22	22	22	22	23	24	24	22	
	women	14	17	26	32	30	34	38	38	38	43	
25-44 yrs	both genders	28	30	41	47	50	53	59	63	64	67	
	men	23	26	35	39	43	42	47	50	49	50	
	women	33	36	48	55	58	63	72	76	79	85	
45-74 yrs	both genders	51	57	68	78	83	92	102	110	114	123	
	men	39	43	51	60	64	73	80	85	87	94	
	women	64	71	85	97	103	111	124	135	141	153	
0-79 yrs	both genders	31	34	43	49	52	56	62	66	68	73	



		men	24	27	34	38	41	44	49	52	52	55
		women	38	42	52	59	63	68	76	81	84	91
	18-79 yrs	both genders	40	44	54	62	66	71	79	85	87	93
		men	31	34	43	49	52	57	62	66	67	70
		women	48	53	66	75	80	87	97	104	108	117
Antimigraine preparations (N02C)	0-74 yrs	both genders	19	19	19	20	20	20	20	21	21	22
		men	8	8	8	9	8	9	9	9	9	9
		women	30	30	31	32	31	32	33	33	33	35
	0-44 yrs	both genders	16	16	17	17	17	17	18	18	18	19
		men	7	7	7	8	8	8	8	8	8	8
		women	26	26	28	27	27	27	28	29	29	31
	0-17 yrs	both genders	3	3	4	4	4	5	5	5	5	5
		men	2	3	3	3	3	3	4	4	4	4
		women	4	4	6	5	5	6	6	7	6	7
	18-24 yrs	both genders	15	16	17	19	17	18	18	18	19	21
		men	6	6	6	7	7	9	8	6	8	7
		women	25	26	29	31	28	29	30	32	30	36
	25-44 yrs	both genders	27	27	27	28	27	26	28	28	28	29
		men	11	11	11	12	11	11	12	11	11	11
		women	44	45	45	44	44	43	45	45	46	48
	45-74 yrs	both genders	23	23	24	24	24	25	25	26	26	26
		men	9	9	10	10	10	10	10	11	11	10
		women	37	37	38	39	39	41	41	42	42	43
	0-79 yrs	both genders	18	18	19	19	19	20	20	20	20	21
		men	8	8	8	8	8	8	9	8	9	9
		women	29	29	31	31	31	31	32	33	33	34
18-79 yrs	both genders	23	23	24	24	24	24	25	25	25	26	
	men	9	9	9	10	10	10	10	10	10	10	
	women	37	37	38	39	39	39	40	41	41	43	
Drugs for mental disorders, incl. hypnotics (N05A, N05C, N05B, N06A)	0-74 yrs	both genders	61	62	63	63	63	63	64	65	65	66



	men	1	1	1	1	1	1	2	2	2	1	
	women	0	0	1	1	1	0	1	1	1	1	
18-24 yrs	both genders	11	12	12	10	11	11	12	11	12	11	
	men	9	10	10	10	11	11	11	11	12	11	
	women	12	13	14	11	11	11	12	11	13	11	
25-44 yrs	both genders	20	20	20	20	21	22	21	20	20	20	
	men	20	20	20	20	21	22	21	21	21	20	
	women	20	20	20	20	20	22	20	19	20	19	
45-74 yrs	both genders	31	30	29	28	28	26	26	26	25	25	
	men	27	26	26	24	24	23	23	24	22	22	
	women	34	34	33	32	31	29	30	29	28	28	
0-79 yrs	both genders	19	19	19	18	18	18	18	17	17	17	
	men	17	17	17	16	17	17	16	17	16	16	
	women	21	20	20	20	19	19	19	18	18	18	
18-79 yrs	both genders	25	25	24	23	23	23	23	22	22	21	
	men	22	22	22	21	21	21	21	21	20	20	
	women	27	27	26	25	25	25	24	23	24	23	
Antidepressants (N06A)	0-74 yrs	both genders	49	51	52	52	52	53	54	55	55	56
		men	34	35	36	36	37	37	38	38	39	39
		women	65	67	70	69	69	70	71	72	73	74
0-44 yrs	both genders	32	32	34	34	35	35	36	37	38	38	
	men	25	25	25	27	26	26	27	28	29	28	
	women	40	41	43	43	43	44	45	47	48	49	
0-17 yrs	both genders	1	1	1	1	2	2	2	2	2	3	
	men	1	1	1	1	1	1	1	1	2	1	
	women	1	2	1	2	2	2	3	3	3	4	
18-24 yrs	both genders	29	29	32	34	33	33	36	38	39	40	
	men	20	22	22	25	23	24	25	26	25	24	
	women	38	37	43	44	44	43	49	52	55	56	
25-44 yrs	both genders	58	59	62	61	62	63	63	65	67	67	

	men	45	45	47	48	48	47	49	50	52	52	
	women	72	74	77	75	76	79	77	81	82	83	
45-74 yrs	both genders	80	82	85	84	84	84	86	85	86	88	
	men	51	53	54	53	54	55	57	56	57	58	
	women	110	113	117	115	114	115	117	116	116	118	
0-79 yrs	both genders	51	52	54	54	54	55	56	56	57	58	
	men	35	36	37	37	37	38	39	39	40	40	
	women	67	69	72	71	71	72	73	74	75	76	
18-79 yrs	both genders	66	68	70	70	70	71	72	73	74	74	
	men	46	47	48	48	48	49	50	51	52	52	
	women	87	89	93	92	92	93	95	95	96	98	
Hypnotics, sedatives and anxiolytics (N05C, N05B)	0-74 yrs	both genders	88	90	92	93	93	92	93	91	90	91
		men	63	65	67	69	70	69	69	69	68	69
		women	113	116	117	118	116	116	117	114	113	114
0-44 yrs	both genders	41	43	45	47	47	47	50	49	48	50	
	men	34	35	37	39	41	40	42	43	42	43	
	women	48	51	53	55	54	54	57	55	55	57	
0-17 yrs	both genders	8	9	10	12	13	12	14	13	13	14	
	men	9	10	11	13	14	14	15	15	14	16	
	women	7	8	9	10	11	11	13	12	12	13	
18-24 yrs	both genders	30	34	35	37	38	38	43	41	43	43	
	men	23	27	26	28	31	30	33	35	34	35	
	women	38	42	45	47	46	47	54	49	53	53	
25-44 yrs	both genders	71	73	76	79	78	78	81	80	79	81	
	men	58	58	62	64	66	64	68	68	68	68	
	women	86	88	91	93	91	92	94	91	91	94	
45-74 yrs	both genders	170	173	173	175	172	171	169	165	163	163	
	men	115	118	119	121	120	120	116	114	113	114	
	women	227	230	229	230	226	224	223	217	215	214	
0-79 yrs	both genders	95	97	98	100	99	98	99	96	96	96	

		men	68	70	72	74	74	73	74	72	72	72
		women	121	124	125	126	124	123	125	121	120	120
	18-79 yrs	both genders	121	123	125	127	125	124	125	122	121	121
		men	86	88	90	92	92	91	92	90	89	90
		women	156	159	160	162	158	158	159	154	153	153
Hypnotics, addictive (N05C excl. N05CH01 and N05CD08)	0-74 yrs	both genders	57	59	60	61	60	59	59	56	55	55
		men	39	41	42	43	43	42	42	41	40	39
		women	75	78	79	79	78	77	77	73	71	71
	0-44 yrs	both genders	23	24	25	26	25	25	25	24	23	23
		men	18	19	20	21	21	20	21	20	19	19
		women	28	29	31	31	30	30	30	28	27	27
	0-17 yrs	both genders	1	2	1	1	1	1	1	1	1	1
		men	1	2	1	1	1	1	1	1	1	1
		women	1	1	1	1	1	2	1	1	1	1
	18-24 yrs	both genders	16	18	21	20	20	20	20	18	17	17
		men	12	13	15	15	17	15	17	15	13	13
		women	21	24	27	25	24	25	24	21	21	21
	25-44 yrs	both genders	43	44	46	47	47	45	47	45	43	43
		men	34	35	37	38	38	37	39	38	36	35
		women	52	53	56	56	56	54	55	51	50	51
	45-74 yrs	both genders	117	121	122	122	121	119	118	113	111	110
		men	77	80	81	83	82	80	79	76	76	74
		women	159	164	163	164	161	159	159	152	148	148
	0-79 yrs	both genders	62	65	65	66	65	64	64	61	59	59
		men	43	45	46	47	46	45	46	44	43	42
		women	82	84	85	85	84	83	82	79	77	77
	18-79 yrs	both genders	81	84	85	86	85	83	83	79	77	77
		men	56	58	60	61	60	59	59	57	56	55
		women	107	110	111	111	109	107	107	102	100	100
ADHD drugs (Attention Deficit Hyperactivity Disorder) (C02AC02 and N06BA except N06BA07)	0-74 yrs	both genders	5	5	6	8	9	10	10	10	11	11

	men	6	7	8	10	11	12	12	12	13	13	
	women	3	3	4	5	7	8	8	8	9	9	
0-44 yrs	both genders	7	8	9	12	13	15	15	15	16	16	
	men	10	11	13	15	17	18	18	18	19	19	
	women	4	5	6	8	10	11	11	12	13	13	
0-17 yrs	both genders	14	15	16	20	21	22	21	20	20	20	
	men	20	21	23	27	29	31	29	28	28	27	
	women	7	8	9	12	13	14	13	11	12	11	
18-24 yrs	both genders	6	8	9	12	14	16	18	19	20	20	
	men	8	10	10	12	14	16	18	20	21	21	
	women	4	6	8	11	14	16	17	19	19	19	
25-44 yrs	both genders	2	3	4	5	7	8	9	10	11	12	
	men	2	3	5	6	8	9	9	10	11	12	
	women	1	2	3	4	6	8	8	10	11	12	
45-74 yrs	both genders	0	0	1	1	1	1	1	2	2	2	
	men	0	1	1	1	1	1	1	2	2	2	
	women	0	0	1	1	1	1	1	2	2	2	
0-79 yrs	both genders	:	:	:	:	:	:	:	:	:	:	
	men	:	:	:	:	:	:	:	:	:	:	
	women	:	:	:	:	:	:	:	:	:	:	
18-79 yrs	both genders	:	:	:	:	:	:	:	:	:	:	
	men	:	:	:	:	:	:	:	:	:	:	
	women	:	:	:	:	:	:	:	:	:	:	
Asthma and chronic obstructive pulmonary disease (COPD) drugs (R03 except R03CA)	0-74 yrs	both genders	70	70	70	70	74	76	76	77	75	76
		men	65	65	65	65	69	71	71	71	69	70
		women	75	77	76	75	79	81	82	83	82	83
0-44 yrs	both genders	60	61	60	61	65	68	68	68	65	65	
	men	61	61	60	61	65	69	68	68	64	64	
	women	59	61	60	61	64	66	67	68	65	66	
0-17 yrs	both genders	74	75	75	77	83	89	90	89	83	83	

	men	86	88	86	89	96	103	102	100	93	92	
	women	60	61	63	65	70	74	77	77	72	72	
18-24 yrs	both genders	48	51	48	50	53	53	53	53	50	49	
	men	43	44	42	44	46	46	46	47	44	40	
	women	53	59	53	56	61	61	60	59	58	58	
25-44 yrs	both genders	54	53	52	52	53	55	55	56	55	56	
	men	47	45	45	45	47	49	48	49	48	49	
	women	61	62	60	59	61	60	62	63	62	64	
45-74 yrs	both genders	87	87	88	87	89	90	92	94	94	96	
	men	72	71	73	72	75	74	77	77	78	80	
	women	103	103	104	101	104	108	108	111	111	113	
0-79 yrs	both genders	72	73	72	72	76	78	78	79	77	78	
	men	67	67	67	68	71	73	73	73	72	72	
	women	77	78	78	77	81	83	84	85	84	85	
18-79 yrs	both genders	71	72	71	71	73	74	75	76	76	77	
	men	62	61	61	61	63	64	64	65	65	66	
	women	82	84	82	81	84	85	86	88	87	89	
Antihistamines (allergy medicines) (R06A, R01AC, R01AD, R01B, S01G)	0-74 yrs	both genders	129	132	134	136	137	135	140	141	138	147
		men	107	109	111	112	116	112	116	116	114	122
		women	151	156	158	160	159	158	164	166	164	172
	0-44 yrs	both genders	125	128	128	131	131	127	133	132	128	137
		men	113	114	115	118	121	114	119	117	113	123
		women	137	142	141	144	142	141	147	147	143	153
	0-17 yrs	both genders	99	101	97	101	100	99	102	98	94	100
		men	113	111	110	113	114	111	115	110	104	113
		women	85	90	85	88	85	87	88	86	82	86
18-24 yrs	both genders	134	137	141	143	148	136	142	142	141	149	
	men	116	117	118	122	131	111	122	118	113	123	
	women	153	159	166	165	166	162	166	168	173	179	
25-44 yrs	both genders	143	147	148	151	152	147	155	155	151	164	

	men	113	116	118	120	123	118	122	123	121	131	
	women	174	180	180	183	181	178	188	190	183	199	
45-74 yrs	both genders	135	138	144	145	146	147	152	156	156	163	
	men	96	99	103	103	106	109	110	115	115	122	
	women	175	180	186	188	188	188	195	200	200	205	
0-79 yrs	both genders	128	131	133	135	136	134	139	140	138	146	
	men	107	108	111	112	115	112	116	116	114	122	
	women	150	155	157	160	159	158	164	166	163	172	
18-79 yrs	both genders	137	141	144	146	148	145	151	153	152	161	
	men	105	107	111	112	116	112	116	118	117	125	
	women	170	175	179	182	181	180	187	191	188	198	
Antihistamines for systemic use (R06)	0-74 yrs	both genders	97	100	101	102	101	97	102	102	100	109
		men	79	81	83	84	84	79	84	83	81	89
		women	115	119	120	122	118	116	120	121	120	130
0-44 yrs	both genders	98	101	101	102	100	95	99	98	95	105	
	men	90	91	93	93	93	86	91	89	86	95	
	women	107	111	109	112	107	105	108	108	106	116	
0-17 yrs	both genders	85	85	83	86	83	81	84	81	78	84	
	men	96	95	95	97	95	92	96	92	88	95	
	women	72	75	71	74	69	70	73	70	67	72	
18-24 yrs	both genders	111	111	115	114	116	105	109	108	106	118	
	men	98	97	99	99	102	87	95	91	86	98	
	women	124	126	133	131	130	125	125	127	129	140	
25-44 yrs	both genders	105	110	110	111	109	103	108	109	106	118	
	men	83	86	89	88	89	81	86	86	84	94	
	women	129	134	132	136	130	126	131	132	129	144	
45-74 yrs	both genders	95	98	102	102	102	101	106	108	108	115	
	men	60	64	67	67	68	68	71	72	73	78	
	women	131	134	138	139	137	136	142	145	144	154	
0-79 yrs	both genders	97	99	101	102	100	97	101	101	100	108	



		men	79	81	83	83	83	79	83	82	81	88
		women	115	118	119	121	118	116	120	121	120	130
	18-79 yrs	both genders	100	103	106	107	106	102	106	108	106	116
		men	74	76	79	79	80	75	79	79	78	86
		women	128	132	134	136	133	130	135	137	136	147

### CellMark Legend

- .. Missing data
- . Not possible to calculate
- : Hidden value

### Description

Users of prescription drugs among 0-79 year olds. Users are defined as people who have been dispensed at least one prescription in the reporting period.

Four measures are available. Use the Measures menu to select:

1. number of users (shown on national level only due to privacy protection)
2. users per 1000 = number of users per 1000 inhabitants of same sex and age per year
3. users per 1000 age standardized = number of users per 1000 inhabitants of same sex and age per year, age standardised. Age standardisation of rates reduces the effect of differing age distributions when groups are compared over time and between geographical regions.
4. Ratio (Norway=100): The ratio between the standardized rate in the county and the national rate for a given year. A ratio of 130 means that the county rate is 30 % higher than the national rate. A ratio of 87 means that the county rate is 13 % lower than the national level.

In the Norwegian Prescription Database, every individual is registered with a pseudonymous serial number which makes it possible to link drug consumption to individuals without knowing who they are. Even if a person has dispensed a prescription for the same drug several times, they are only counted as a user once.

Drug consumption cannot be assumed to be synonymous with disease prevalence. The exception is the use of drugs to treat diabetes mellitus, which can be considered a good indicator for prevalence of diabetes. A lot of patients use multiple drugs, e.g. both anti-depressives and hypnotics, so will be included in both groups. It is therefore not possible to simply add the number of users in two groups of drugs to find out how many users there are in total.

Figures in Norhealth may vary slightly from the Norwegian Prescription Database because data may have been extracted from the main database at different times.

Drugs are classified according to the ATC system (see below).

The following groups of drugs are included \*:

All drugs in total

Diabetes drugs (A10)

- Insulins and analogues (A10A)

Cardiovascular disease, treatment/prevention (C)

- Cardiovascular disease, treatment/prevention, except Lipid modifying agents (C except C10)

- Lipid modifying agents (C10)

Painkillers (analgetics) (M01A, N02A, N02B)

- Antiinflammatory and antirheumatic products, non-steroids (M01A)

- Painkillers, Opioids (N02A)

- Painkillers, other (N02B)

- Antimigraine preparations (N02C)

Drugs for mental disorders (N05A, N06A)

- Antipsychotics (N05A)

- Antidepressants (N06A)

Hypnotics and anxiolytics (N05B, N05C)

- Hypnotics (N05C)

- Hypnotics, addictive (N05C excl. N05CH01 and N05CD08)

ADHD drugs (Attention Deficit Hyperactivity Disorder) (C02AC02 and N06BA except N06BA07)

Asthma and chronic obstructive pulmonary disease (COPD) drugs (R03 except R03CA)

Antihistamines (allergy medicines) (R06A, R01AC, R01AD, R01B, S01G)  
- Antihistamines for systemic use (R06A)

Prescriptions for antibiotics are presented in a separate, neighbouring table.

Data on Blood glucose lowering drugs, excluding insulins (A10B) are presented under Health and disease/ Disease groups/ Type 2 diabetes, indicators.

News, March 2019:

- New subgroup: Hypnotics, addictive - comprising all hypnotics except melatonin and midazolam.

- ADHD drugs now include guanfacin (C02AC02).

- Drugs against asthma and chronic obstructive pulmonary disease (COPD) now exclude R03CA. The former group "Asthma and COPD (R03)" has been discontinued.

Drugs are classified according to the ATC-system (Anatomic, Therapeutic, Chemical classification). By using this international classification system one can make statistics of drug consumption groups at 5 different levels, including from figures that show total use of all preparations classified under a main group (1st level, e.g. group C - Heart and circulation), figures for the different sub-groups (2nd, 3rd and 4th level) and down to figures that show use of each active ingredient.

Further information about the Norwegian Prescription Database can be found at [www.norpd.no](http://www.norpd.no).

See also Drug Consumption in Norway at [www.drugconsumption.no](http://www.drugconsumption.no).

\* Some of the drugs can be bought without a prescription, e.g. in small packages. Such use is not included in the statistics.

---

### **Rationale for indicator**

For many diseases, we have insufficient data on prevalence. Drug use is not synonymous with disease prevalence, but can be an indicator for the prevalence of a disease.

---

### **Source**

Norwegian Institute of Public Health, Department of Pharmacoepidemiology

---

### **Collection**

The Norwegian Prescription Database contains information on all prescriptions dispensed from Norwegian pharmacies for both human and animal use. The register only contains information that directly or indirectly concerns prescriptions. Information about the patient and prescriber is pseudonymous.

---

### **Interpretation and sources of error**

Purchases of over the counter drugs from a pharmacy or grocery store are not included. People over 80 years are excluded because there are varying proportions in each county who live at institutions where drugs are provided by the institution rather than via private prescriptions. Figures are also not presented for inappropriate combinations of age and drug groups, for example anti-dementia medicines for children.

---

### **Data quality**

The data quality is very good.

---

### **Statistical analysis**

Age standardization is done using direct standardization. The standard population is the sum of men and women in each age group in Norway per 1.January 2012.

---

### **When numbers are missing**

Statistics based on fewer than five cases are hidden for privacy reasons. The same is done where the population segment from which the data are collected is less than ten.

If more than 20 per cent of the numbers in a time series are hidden for privacy reasons, the entire time series is concealed so as not to create a false impression of the situation in the county. Time series are also hidden where more than 50 per cent of the numbers in the time series are based on 6 or fewer cases.

---

### **Time periods**

2005-2021

---

**Geographical level**

Country, health region, counties

---

**Gender**

Both genders, men, women

---

**Age groups**

0-74 years, 0-44 years (0-17, 18-24, 25-44), 45-74 years. Additionally, 0-79 years and 18-79 years.

---

**Frequency of updates**

Annually

---

**Last updated**

4/27/22

---

**Keywords**

Click on a keyword to search for similar indicators.

- Antibiotics
  - Antihypertensives
  - Antipsychotics
  - Anxiety
  - Asthma
  - Betablockers
  - Blood lipids
  - Blood pressure
  - Blood sugar
  - Calcium antagonists
  - Cholesterol
  - Contraceptives
  - Dementia
  - Diabetes
  - Drugs
  - Estrogen
  - Hypertension
  - Hypnotics
  - Insulin
  - Medicine
  - Menopause
  - Obesity
  - Prescription database
  - Sedatives
- 

**Fact sheets**

Below are links to relevant fact sheets, articles and reports. These may describe trends over time in the Norwegian population or differences by sex, age group, geographical region or socioeconomic status:

- [Topic: Drug consumption](#)
- [Topic: Pain](#)
- [Facts on hypertension \(in Norwegian only\)](#)
- [Chronic Obstructive Pulmonary Disease \(COPD\) in Norway - Public Health Report](#)